NOTCH1 and metastatic neoplasm: Activating NOTCH1 mutations are reported in ∼ 20% of cases with recurrent and/or metastatic disease [16], and are associated with a more aggressive disease phenotype and poor overall survival (OS) as compared to patients with wild-type NOTCH1 [17].